Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology
Pierre Dourlen(Inserm), Bart Dermaut(Inserm), Francisco-José Fernández-Gómez(Inserm), Philippe Amouyel(Institut Pasteur de Lille), C. Delay(Inserm), Clément Dupont(Inserm), Nicolas Sergeant(Inserm), Luc Buée(Inserm), Hélène Obriot(Inserm), Céline Bellenguez(Inserm), Julien Chapuis(Inserm), Hilkka Soininen, Mikko Hiltunen(University of Eastern Finland), Alexis Bretteville(Inserm), Nicolas Malmanche(Universidade do Porto), Raphaëlle Caillierez(Inserm), Yoann Sottejeau(Inserm), Benjamin Grenier‐Boley(University of Bonn), Farida Abdelfettah(Inserm)
Cited by 119
Related Papers
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
|The Lancet|2016|4.4k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.6k